🎙️The 1st episode of ESC CardioTalk: Cardio-Oncology is now LIVE🫀🩺
‘Which Patients Should Receive Pre-Treatment Cardiac Screening Before Chemotherapy or Immunotherapy?’
Discover expert insights and stay updated with the latest discussions🌍
👉Listen now https://t.co/YvILtCLtBf
❤️🩹 Heart failure can already be present before chemotherapy🚨or develop as a side effect of cancer treatment💊
How can we better prevent, monitor & manage cancer therapy-related cardiac dysfunction? 🩺🎗️#CardioOncology#HFA2026@escardio
Ahead of World Cancer Day (4 Feb) 🗓️ we’re spotlighting our Top 10 #CardioOnc articles📚—showcasing the field’s momentum, collaboration🤝🫀and the power of multidisciplinary care. Stay tuned! 🚀 https://t.co/WWtctdgjjD #ESCardioOnco26
🌍 The ESC Council of Cardio-Oncology #CardioOnc at #HFA2026 in beautiful Barcelona🇪🇸 New projects, new research and new initiatives shaping the future 🚀
📍Want to know more? Join the Council and take part in the Vienna Congress in June 2026🇦🇹
🩸 Cancer-associated VTE: NOAC dose matters❓In a large RCT, extended reduced-dose apixaban (2.5 mg bid) was noninferior to full dose X recurrent VTE and led to less clinically relevant bleeding ⚖️ Efficacy preserved, safety improved🫀#CardioOncology
🔗doi: 10.1056/NEJMoa2416112
The 2nd Edition of #ESCardioOnco26 is back!🫀
Join the global #cardiooncology community in Vienna, 19–20 June 2026!📚
⏰ Key deadlines you don’t want to miss:
- 29 Jan 2026: Abstract submission
- 05 Feb 2026: Clinical case
🔗 Submit now!: https://t.co/ThuFp5hklX
@escardio
⚠️ New from #EHJ🗞️ICI-associated myocarditis is different from other myocarditis.
From a 17-country registry (n=748), a new risk score predicts severe cardiomyotoxic outcomes using troponin, thymoma, QRS voltage, LVEF & neuromuscular symptoms📊🔗doi: 10.1093/eurheartj/ehaf315.
⚠️The #ESCardioCRT is a unique event aimed at overcoming communications’ barriers and promote dialogue in #CardioOnc🫀The @escardio is devoted to the CV Health of patients with cancer through the #COCouncil@ESCardioOnco
1 in 3 patients develops cardio toxicity due to oncological treatments.
Dr. Alexander Lyon summarizes discussions at #ESCardioCRT on creating a framework for improving cardiovascular safety by integrating:
⏺️ oncology pharmacotherapy
⏺️ CV pharmacotherapy
⏺️ imaging
⏺️ CV biomarkers
⏺️ digital health and data processing
⏺️ regulation of medication and trials monitoring
Listen to his insights and join us for the #ESCardioOnco26 conference, a unique environment where the full circle above will be covered https://t.co/6D9KWZcT6j
#cardioonco #cardioonc
The first #ESCardioCRT edition of the year kicked off with a programme focused on cardiovascular safety in the context of #CancerCare
ESC President-Elect Cecilia Linde shares how cardio toxicity mitigation as a result of cancer therapy must become top of mind for health professionals, healthcare industry, and regulators 👇
#patientsfirst #cardioonco #cardioonc
Explore the latest advances in #CardioOncology with leading experts in the field🫀
The second COOL Group webinar is coming up, don’t miss it!
Join the outstanding faculty: Drs #PietroAmeri, #AlessandraGhigo, & #WouterMeijers
Register now: https://t.co/GFXfrTp0zf
@escardio
🫀The ESC CRT on #CardioOncology has just successfully concluded, bringing together experts from academia, regulatory bodies, industry and patient organisations for a strategic dialogue🤝Look forward to discuss the future of #CardioOnc in Vienna #ESCardioOnco2026 Conference⚠️
We’re thrilled to welcome you to #EACVI2025, taking place 11–13 December in Vienna — a landmark event uniting the full spectrum of cardiovascular imaging!
Echo, CMR, Nuclear, CT: all together for 3 days of cutting-edge multimodality learning.
Advancing imaging. Enhancing patient care. 🚀❤️
https://t.co/V3XUoZtqrq
https://t.co/Vi0zUj5yTT
Resérvate la fecha para #CardioTox25:
🗓 4–6 de noviembre de 2025 | 📍 Madrid
El congreso internacional de referencia en cardio-oncología vuelve con su 11.ª edición. Tres días para compartir avances, conectar disciplinas y fortalecer el cuidado CV en pacientes oncológicos.
👥 Oncólogos, hematólogos, cardiólogos, médicos de primaria, enfermería y profesionales.
Expertos nacionales e internacionales te esperan con las últimas novedades y aplicaciones clínicas reales.
🔗 Inscríbete y forma parte del futuro de la cardio-oncología.
https://t.co/49l2O2mgYk
@TeresaLpezFdez1@DrRaulCordoba@CNIC_CARDIO@_SEOM@preventiva_SEC@clinica_sec@sehh_es@cardiooncoSEC@SEHHJoven@SEOR_ESP
🫀Atrial arrhythmias are common in cancer, but cancer-specific guidance is limited. This review, from @Dr_Mike_Fradley, Robert Monsour (@PennIMResidents), & #CardioOnc Fellows Nick Wilcox & Angie Seo, outlines where we are now & where we need to go🔗https://t.co/NlEbbmk5dp